Key points are not available for this paper at this time.
This study investigated the feasibility of GluCEST at 3.0 T for detecting the change of glutamate in the human brain after stroke. The imaging capability of glutamate is validated on the phantom and human brain, respectively. Glutamate at physiological concentrations could be detected by in vitro MRI. The findings of an in vivo investigation revealed that the GluCEST signal of stroke patients differs from that of healthy individuals and that this difference may be detected by 3.0 T MRI. This work provides fresh insights into the use of endogenous glutamate MRI imaging.
Qin et al. (Wed,) studied this question.